BioCardia disclosed that its heart failure stem cell therapy failed to hit on all three measures that comprised the primary endpoint of a Phase III study at an interim analysis.
In 102 patients, there was no statistically significant difference in rates of death, major cardiovascular events and performance on the six-minute walk test (6MWT) at one year between those who got BioCardia’s treatment and a sham, according to BioCardia’s press release Tuesday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.